Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Economics of chronic heart failure.

Berry C, Murdoch DR, McMurray JJ.

Eur J Heart Fail. 2001 Jun;3(3):283-91. Review.

2.

Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults.

Rich MW.

J Am Geriatr Soc. 1997 Aug;45(8):968-74. Review.

PMID:
9256850
3.

[Economic significance of heart failure. An overview of costs and economics of therapy].

Szucs TD, Sokolovic E.

Herz. 2000 Aug;25(5):538-46. German.

PMID:
10993002
4.

What are the costs of heart failure?

Braunschweig F, Cowie MR, Auricchio A.

Europace. 2011 May;13 Suppl 2:ii13-7. doi: 10.1093/europace/eur081.

PMID:
21518742
5.

Hospital cost effect of a heart failure disease management program: the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial.

Gregory D, Kimmelstiel C, Perry K, Parikh A, Konstam V, Konstam MA.

Am Heart J. 2006 May;151(5):1013-8.

PMID:
16644325
6.

Drug copayment and adherence in chronic heart failure: effect on cost and outcomes.

Cole JA, Norman H, Weatherby LB, Walker AM.

Pharmacotherapy. 2006 Aug;26(8):1157-64.

PMID:
16863491
7.

Economic implications of treatment guidelines for congestive heart failure.

Shibata MC, Nilsson C, Hervas-Malo M, Jacobs P, Tsuyuki RT.

Can J Cardiol. 2005 Dec;21(14):1301-6.

PMID:
16341301
8.

The economic burden of congestive heart failure in a managed care population.

Xuan J, Duong PT, Russo PA, Lacey MJ, Wong B.

Am J Manag Care. 2000 Jun;6(6):693-700.

9.

[Impact of telemetric management on overall treatment costs and mortality rate among patients with chronic heart failure].

Kielblock B, Frye Ch, Kottmair S, Hudler T, Siegmund-Schultze E, Middeke M.

Dtsch Med Wochenschr. 2007 Mar 2;132(9):417-22. German.

PMID:
17315117
10.

Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment.

Choy CK, Spencer AP, Nappi JM.

Pharmacotherapy. 2007 May;27(5):707-14.

PMID:
17461706
11.

Financial aspects of heart failure programs of care.

Stewart S.

Eur J Heart Fail. 2005 Mar 16;7(3):423-8.

12.

Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.

Am Heart J. 2004 Jul;148(1):122-8.

PMID:
15215801
13.

The management of heart failure in Sweden.

Cline CM, Boman K, Holst M, Erhardt LR; Swedish Society of Cardiology Working Group for Heart Failure.

Eur J Heart Fail. 2002 Jun;4(3):373-6.

14.

[Costs and benefits of heart failure treatment].

Gaspoz JM.

Schweiz Med Wochenschr. 1999 Jan 30;129(4):131-7. French.

PMID:
10087590
15.
16.

Advances in the management of acute and chronic decompensated heart failure.

Lowery SL, Massaro R, Yancy CW Jr.

Lippincotts Case Manag. 2004 Jan-Feb;9(1):4-18; quiz 19-20. Review.

PMID:
15076832
17.

Epidemiology of heart failure in primary care in Madeira: the EPICA-RAM study.

Ceia F, Fonseca C, Azevedo I, Mota T, Morais H, Matias F, Costa C, Gouveia-Oliveira A; Representação dos Investigadores do EPICA-RAM.

Rev Port Cardiol. 2005 Feb;24(2):173-89. English, Portuguese.

18.

Heart failure: a growing public health problem.

Eriksson H.

J Intern Med. 1995 Feb;237(2):135-41. Review.

PMID:
7852915
19.

The health care costs of heart failure in Sweden.

Rydén-Bergsten T, Andersson F.

J Intern Med. 1999 Sep;246(3):275-84.

20.

Economic burden of cardiovascular events and fractures among patients with end-stage renal disease.

Doan QV, Gleeson M, Kim J, Borker R, Griffiths R, Dubois RW.

Curr Med Res Opin. 2007 Jul;23(7):1561-9.

PMID:
17555611

Supplemental Content

Support Center